



ATTORNEYS AT LAW



Robert Greene Strome
 Jorge A. Goldstein
 David K. Connell
 Robert J. Conrad
 Thomas G. Durkin
 Michele A. Cimbalia
 Michael B. Ray
 Robert L. Scholz
 Eric J. Stoffle
 Michael Q. Lee
 Steven R. Ludwig
 John M. Coven
 Richard J. Coven
 Donald J. Fenstermacher
 Timothy J. Shea, Jr
 Michael V. Messinger
 Judith U. Kim
 Patrick E. Garrett

Jeffrey L. Helvey
 Eldora L. Ellison
 Thomas C. Fiala
 Dennis M. Gammie
 Peter A. Jackson
 Jeffrey S. Weaver
 Brian J. Del Buono
 Mark Fox Evans
 Edward J. Fife
 Vincent L. Capuano
 Virgil Lee Beaston
 Theodore A. Wood
 Elizabeth A. Barnes
 Joseph S. Orosz
 Frank R. Cunningham
 Daniel A. Klein
 Jason D. Eisenberg
 Michael D. Specht

Tracy L. Mueller
 Jon E. Wright
 LuAnne M. DeGrazia
 Ann L. Johnson
 Helene C. Carbon
 Cynthia M. Roach
 Timothy A. Doyne
 Gaby L. Longworth
 Lori A. Koenig
 Laura A. Vogel
 Bryan S. Wade
 Badria M.S. Ali
 Shelly S. Carroll
 Arthur E. D'Amato
 Michelle K. Holoubek
 Marzia A. Rose
 Young Tang
 Christopher J. Webb

W. Blaize Coblenz*
 James J. Pohl*
 John T. Harris
 Mark W. Ryggle
 Kevin W. McCleary
 Michael R. Matik*
 Registered Patent Agents*
 Karen R. Markowitz
 Matthew J. Dowd
 Karen L. Koenig
 Bryan L. Skeath
 Robert A. Schwartzman
 Victoria S. Rutherford
 Simon J. Elliott
 Julie A. Hinder
 Rita Mukherjee

Scott M. Woodhouse
 Lillian Di Nola-Berzon
 Peter A. Socciaris
 Jeffrey K. Mills
 Daniel L. Letting
 Lori Branson
 Steven C. Oppenheimer

Of Counsel
 Edward J. Becker
 Kenneth C. Bass III
 Marvin C. Guchie
 *Admitted only in Maryland
 *Admitted only in Virginia
 *Practice Limited to
 Federal Agencies

September 15, 2006

WRITER'S DIRECT NUMBER:
 (202) 772-8782
 INTERNET ADDRESS:
 BCORLENT@SKGKF.COM

Art Unit 1645

Commissioner for Patents
 PO Box 1450
 Alexandria, VA 22313-1450

Re: U.S. Utility Patent Application No. 10/521,010
 U.S. National Phase of Appl. No. PCT/AU2003/000910
 Int'l Filing Date: July 14, 2003
 For: **Expression of Hydrophobic Proteins**
 Inventors: Elizabeth Ann WEBB *et al.*
 Our Ref: 2349.0010000/JUK/WBC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement Filing under 37 C.F.R. § 1.97(b);
2. Form PTO/SB/08A (1 page) citing seven (7) documents (US1 and FP1-FP6);
3. Copies of six (6) cited documents (FP1-FP6);
4. Form PTO/SB/08B (1 page) citing four (4) documents (NPL1-NPL4);
5. Copies of four (4) cited documents (NPL1-NPL4); and
6. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
September 15, 2006
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



William B. Coblenz
Attorney for Applicants
Registration No. 57,104

JUK/WBC:cpn
Enclosures

583235_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Elizabeth Ann WEBB *et al.*

Appl. No.: 10/521,010

Int'l Filing Date: July 14, 2003

For: **Expression of Hydrophobic Proteins**

Confirmation No.: 2794

Art Unit: 1645

Examiner: *To Be Assigned*

Atty. Docket: 2349.0010000/JUK/WBC

**Information Disclosure Statement
Filing under 37 C.F.R. § 1.97(b)**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents **FP1-FP6** and **NPL1-NPL4** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), a copy of the U.S. patent, document **US1**, cited on the attached Form PTO/SB/08A is not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



William B. Coblenz
Attorney for Applicants
Registration No. 57,104

Date: September 15, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

530481_1.DOC

Atty. Dkt. No. 2349.0010000/JUK/WBC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. PATENT AND TRADEMARK OFFICE, U.S. DEPARTMENT OF COMMERCE
in a collection of information unless it contains a valid CMMR control number.

Do not submit a collection of information unless it contains a valid UMS control number.

Substitute for ~~TRADE~~ 449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 1

Complete if Known

Application Number	10/521,010
Int'l Filing Date	July 14, 2003
First Named Inventor	Elizabeth Ann WEBB
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	2349.0010000/JUK/WBC

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

530487 1.DOC

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional): *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.4. *Enter Office that issued the document, by the two-letter code (WIPO) Standard ST 3 - *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. FAX TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

1

of

1

Application Number	10/521,010
Int'l Filing Date	July 14, 2003
First Named Inventor	Elizabeth Ann WEBB
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	2349.0010000/JUK/WBC

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	NPL1	Deavin, A.J., et al., "Statistical Comparison of Established T-Cell Epitope Predictors Against a Large Database of Human and Murine Antigens," <i>Mol. Immunol.</i> 33:145-155, Elsevier Science Ltd. (1996)	
	NPL2	Firat, H., et al., "Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV-1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice," <i>Eur. J. Immunol.</i> 31:3064-3074, Wiley-VCH Verlag GmbH (October 2001)	
	NPL3	Le, T.T.T., et al., "Cytotoxic T cell polypeptide vaccines delivered by ISCOMSS," <i>Vaccine</i> 19:4669-4675, Elsevier Science Ltd. (September, 2001)	
	NPL4	Shi, Y.P., et al., "Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate," <i>Vaccine</i> 18:2902-2914, Elsevier Science Ltd. (2000)	

530488_1.DOC

/Michael Berlin/

Examiner Signature	Date Considered	07/18/2008
--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

If you need assistance in completing this form, call 1-800-767-3767 or 703-557-0999 and select option 2.